FibroGen (FGEN) Misses Q3 EPS by 15c
- Futures range-bound ahead of long weekend break
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Yen on intervention watch; Asia shares creep higher
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
FibroGen Reports Third Quarter 2018 Financial Results
November 8, 2018 4:02 PM ESTRoxadustat New Drug Applications under Review in China and JapanPhase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, Â today reported financial results for the third quarter of 2018 and provided an update on the companys recent developments.
With new drug applications for roxadustat in anemia associated... More